Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties

The use of Lenalidomide (LEN), to reverse tumor-mediated immune suppression and amplify multiple myeloma-specific immunity is currently being explored. Particularly, LEN effects on dendritic cells (DCs) are still unclear. In this study, we investigated the potential effect of LEN on DC differentiati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Costa, Federica, Vescovini, Rosanna, Bolzoni, Marina, Marchica, Valentina, Storti, Paola, Toscani, Denise, Accardi, Fabrizio, Notarfranchi, Laura, Dalla Palma, Benedetta, Manferdini, Cristina, Manni, Sabrina, Todaro, Giannalisa, Lisignoli, Gina, Piazza, Francesco, Aversa, Franco, Giuliani, Nicola
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581092/
https://ncbi.nlm.nih.gov/pubmed/28881793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18085
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars